AstraZeneca said net income fell 18% in the third quarter, hurt by continued generic competition for its top drugs. The company also said Marc Dunoyer is taking over as chief financial officer.
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304073204579168943850800638.html?mod=pls_whats_news_us_business_f
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304073204579168943850800638.html?mod=pls_whats_news_us_business_f
Nessun commento:
Posta un commento